Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses

References

• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300.
   PubMed Web of Science ®Google Scholar
• Rolfes MA, Flannery B, Chung JR, et al. Effects of influenza vaccination in the United States during the 2017–2018 influenza season. Clin Infect Dis. 2019;69(11):1845–1853.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Gaglani M, Ghamande S, et al. Vaccine effectiveness against influenza-associated hospitalizations among adults, 2018-2019, US hospitalized adult influenza vaccine effectiveness network. J Infect Dis. 2021;224(1):151–163.
   Web of Science ®Google Scholar
• Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929–4944.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006;5(12):1015–1025.
   PubMed Web of Science ®Google Scholar
• Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun. 2013;4:2854.
   PubMed Web of Science ®Google Scholar
• Takashita E, Fujisaki S, Shirakura M, et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill. 2016;21(24):30258.
   Google Scholar
• Samson M, Pizzorno A, Abed Y, et al. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98(2):174–185.
   PubMed Web of Science ®Google Scholar
• Kim HM, Lee N, Kim M-S, et al. Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea. Virol J. 2020;17(1):94.
   Web of Science ®Google Scholar
• Wang J, Li F, Ma C. Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses. Biopolymers. 2015;104(4):291–309.
   PubMed Web of Science ®Google Scholar
• Wang J, Qiu JX, Soto C, et al. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr Opin Struct Biol. 2011;21(1):68–80.
   Web of Science ®Google Scholar
• Jalily PH, Duncan MC, Fedida D, et al. Put a cork in it: plugging the M2 viral ion channel to sink influenza. Antiviral Res. 2020;178:104780.
   PubMed Web of Science ®Google Scholar
• Hong M, DeGrado WF. Structural basis for proton conduction and inhibition by the influenza M2 protein. Protein Sci. 2012;21(11):1620–1633.
   Web of Science ®Google Scholar
• Wang J, Wu Y, Ma C, et al. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc Natl Acad Sci U S A. 2013;110(4):1315–1320.
   PubMed Web of Science ®Google Scholar
• Musharrafieh R, Ma C, Wang J. Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses. Eur J Pharm Sci. 2020;141:105124.
   Web of Science ®Google Scholar
• He W, Zhang W, Yan H, et al. Distribution and evolution of H1N1 influenza A viruses with adamantanes-resistant mutations worldwide from 1918 to 2019. J Med Virol. 2021;93(6):3473–3483.
   PubMed Web of Science ®Google Scholar
• Hu Y, Hau RK, Wang Y, et al. Structure-property relationship studies of influenza A virus AM2-S31N proton channel blockers. ACS Med Chem Lett. 2018;9(11):1111–1116.
   Web of Science ®Google Scholar
• Wang Y, Hu Y, Xu S, et al. In vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant influenza A viruses. J Med Chem. 2018;61(3):1074–1085.
   Web of Science ®Google Scholar
• Hu Y, Wang Y, Li F, et al. Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. Eur J Med Chem. 2017;135:70–76.
   PubMed Web of Science ®Google Scholar
• Li F, Hu Y, Wang Y, et al. Expeditious lead optimization of isoxazole-containing influenza A virus M2-S31N inhibitors using the suzuki-miyaura cross-coupling reaction. J Med Chem. 2017;60(4):1580–1590.
   PubMed Web of Science ®Google Scholar
• Li F, Ma C, Hu Y, et al. Discovery of potent antivirals against amantadine-resistant influenza A viruses by targeting the M2-S31N proton channel. ACS Infect Dis. 2016;2(10):726–733.
   Web of Science ®Google Scholar
• Li F, Ma C, DeGrado WF, et al. Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel. J Med Chem. 2016;59(3):1207–1216.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma C, Wang J, et al. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. J Med Chem. 2013;56(7):2804–2812.
   Web of Science ®Google Scholar
• Wu Y, Canturk B, Jo H, et al. Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel. J Am Chem Soc. 2014;136(52):17987–17995.
   Web of Science ®Google Scholar
• Ye J, Sorrell EM, Cai Y, et al. Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog. 2010;6(10):e1001145.
   Web of Science ®Google Scholar
• Ferreri LM, Ortiz L, Geiger G, et al. Improved detection of influenza A virus from blue-winged teals by sequencing directly from swab material. Ecol Evol. 2019;9(11):6534–6546.
   Web of Science ®Google Scholar
• Musharrafieh R, Lagarias P, Ma C, et al. Investigation of the drug resistance mechanism of M2-S31N channel blockers through biomolecular simulations and viral passage experiments. ACS Pharmacol Transl Sci. 2020;3(4):666–675.
   Google Scholar
• Musharrafieh R, Ma C, Wang J. Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Res. 2018;153:10–22.
   Web of Science ®Google Scholar
• Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol. 1938;27(3):493–497.
   Google Scholar
• Hu Y, Zhang J, Musharrafieh R, et al. Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral. Int J Mol Sci. 2017;18(9):1929.
   Web of Science ®Google Scholar
• Hu Y, Zhang J, Musharrafieh RG, et al. Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses. Antiviral Res. 2017;145:103–113.
   PubMed Web of Science ®Google Scholar
• Ma C, Zhang J, Wang J. Pharmacological characterization of the spectrum of antiviral activity and genetic barrier to drug resistance of M2-S31N channel blockers. Mol Pharmacol. 2016;90(3):188–198.
   Web of Science ®Google Scholar
• Hu Y, Musharrafieh R, Ma C, et al. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. Antiviral Res. 2017;140:45–54.
   PubMed Web of Science ®Google Scholar
• Hu Y, Meng X, Zhang F, et al. Thein vitroantiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg Microbes Infect. 2021;10(1):317–330.
   PubMed Web of Science ®Google Scholar
• Ma C, Hu Y, Zhang J, et al. Pharmacological characterization of the mechanism of action of R523062, a promising antiviral for enterovirus D68. ACS Infect Dis. 2020;6(8):2260–2270.
   Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1.
   PubMed Web of Science ®Google Scholar
• Sutton TC, Obadan A, Lavigne J, et al. Genome rearrangement of influenza virus for anti-viral drug screening. Virus Res. 2014;189:14–23.
   Web of Science ®Google Scholar
• Girard MP, Cherian T, Pervikov Y, et al. A review of vaccine research and development: human acute respiratory infections. Vaccine. 2005;23(50):5708–5724.
   PubMed Web of Science ®Google Scholar
• Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–5096.
   PubMed Web of Science ®Google Scholar
• Paul Glezen W, Schmier JK, Kuehn CM, et al. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103(3):e43–e51.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Amicizia D, Lai PL, et al. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Hum Vaccin Immunother. 2012;8(1):21–28.
   PubMed Web of Science ®Google Scholar
• Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis. 2020;39(7):1201–1208.
   PubMed Web of Science ®Google Scholar
• Carr S, Ilyushina NA, Franks J, et al. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J. 2011;30(4):284–288.
   PubMed Web of Science ®Google Scholar
• O'Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol. 2019;35:14–18.
   PubMed Web of Science ®Google Scholar
• Yoshii N, Tochino Y, Fujioka M, et al. The comparison of the efficacy of Baloxavir and neuraminidase inhibitors for patients with influenza A in clinical practice. Internal Med. 2020;59(12):1509–1513.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Kitazawa T, Ota Y. Clinical efficacy of baloxavir marboxil in the treatment of seasonal influenza in adult patients: a prospective observational study. Int J Gen Med. 2020;13:735–741.
   PubMed Web of Science ®Google Scholar
• Imai M, Yamashita M, Sakai-Tagawa Y, et al. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nat Microbiol. 2020;5(1):27–33.
   Web of Science ®Google Scholar
• Ikematsu H, Kawai N, Tani N, et al. Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018–2019 influenza season. J Infect Chemother. 2020;26(4):400–402.
   Web of Science ®Google Scholar
• Musharrafieh R, Lagarias PI, Ma C, et al. The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers. Mol Pharmacol. 2019;96(2):148–157.
   PubMed Web of Science ®Google Scholar
• Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther. 2012;17(1 Pt B):143–157.
   PubMed Web of Science ®Google Scholar
• Donner B, Bader-Weder S, Schwarz R, et al. Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf. 2011;20(5):532–543.
   Web of Science ®Google Scholar
• Baz M, Carbonneau J, Rheaume C, et al. Combination therapy with oseltamivir and favipiravir delays mortality but does not prevent oseltamivir resistance in immunodeficient mice infected with pandemic A(H1N1) influenza virus. Viruses. 2018;10(11):610.
   Web of Science ®Google Scholar
• Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017;17(12):1255–1265.
   PubMed Web of Science ®Google Scholar
• Bird NL, Olson MR, Hurt AC, et al. Oseltamivir prophylaxis reduces inflammation and facilitates establishment of cross-strain protective T cell memory to influenza viruses. PLoS One. 2015;10(6):e0129768.
   PubMed Web of Science ®Google Scholar
• Ilyushina NA, Hoffmann E, Salomon R, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12(3):363–370.
   Web of Science ®Google Scholar
• Smee DF, Hurst BL, Wong M-H, et al. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother. 2009;53(5):2120–2128.
   Web of Science ®Google Scholar
• Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008;52(11):3889–3897.
   Web of Science ®Google Scholar